REG - Logistics Dev Grp - Further Alliance Pharma plc Investment

Logistics DevelopmentAnnouncement

23/02/2023 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230223:nRSW8890Qa&default-theme=true

RNS Number : 8890Q  Logistics Development Group PLC  23 February 2023

23 February 2023

 

Logistics Development Group plc

 

("LDG") or the "Company")

 

Further Alliance Pharma plc Investment

 

 

LDG is pleased to announce that, further to its announcement on 22 December
2022, it has purchased an additional 18,686,042 ordinary shares in Alliance
Pharma plc ("Alliance") (LON:APH), at an average price of £0.5911 per
ordinary share, for a total cash consideration of £3,452,782.

 

Following these purchases, LDG is interested in approximately 3.46% of
Alliance's issued share capital.

 

Alliance is an international healthcare group founded in 1996 and
headquartered in the United Kingdom. The company acquires, markets, and
distributes consumer healthcare and prescription medicine products.

 

For the year ended 31 December 2021, Alliance reported an underlying pre-tax
profit of £42.2 million. As at 30 June 2022, Alliance reported net assets of
£296.9 million.

 

 

For enquiries:

 

 Logistics Development Group plc     Via FTI Consulting
 FTI Consulting                      +44 (0) 20 3727 1340

 Nick Hasell

 Alex Le May

 Cally Billimore

 Strand Hanson Limited               +44 (0) 20 7409 3494

 (Financial and Nominated Adviser)

 James Spinney

 James Dance

 Abigail Wennington

 Investec Bank plc                   +44 (0) 20 7597 5970

 (Broker)

 Gary Clarence

 Harry Hargreaves

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXXLFLXLLLBBD